PGEN Earnings

PGEN reported its FY2025Q4 earnings on 2026-03-09, showcasing a revenue of against an estimate of 5.53M, resulting in a 0% surprise. The EPS was 0, surpassing the expected -0.09 by 0%. The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following PGEN's FY2025Q4 earnings announcement on 2026-03-09, the stock price moved by 0% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, PGEN's stock price tends to shift by an average of 7.12% in the 10 days leading up to earnings and 3.75% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate PGEN's annual revenue to reach 8.29M, while the EPS is projected at -0.08. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between PGEN's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, PGEN's stock price typically moves by 7.12% in the 10 days before its earnings and 3.75% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of -0.08 and revenue of 8.29M.

The earnings call summary and Q&A reveal positive aspects: expansion plans, optimistic guidance on reaching cash breakeven, and strong market momentum for PAPZIMEOS. Despite some risks like cold chain logistics and regulatory compliance, the company’s financial health is stable with $123.6 million in cash and investments. The Q&A reassures on patient reimbursement and market adoption. The stock price is likely to react positively in the short-term, driven by optimistic guidance and market expansion strategies.